Pasithea therapeutics confirms receipt of unsolicited proposal from lucy scientific discovery inc.

Palo alto, calif. and miami, june 06, 2023 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, confirmed it has received an unsolicited proposal from lucy scientific discovery inc. (nasdaq: lsdi) (“lucy”) to acquire all outstanding shares of pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of lucy common stock.
KTTA Ratings Summary
KTTA Quant Ranking